Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498388 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2NPSR1GAA | |
| SCHEMBL1498335 | 1.00 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2NPSR1GAA | |
| SCHEMBL1498515 | 0.82 | TDP1 (0.40) | KDM4EALDH1A1SMN1; SMN2GAAPOLB | |
| SCHEMBL1498513 | 0.82 | TDP1 (0.40) | KDM4EALDH1A1SMN1; SMN2GAAPOLB | |
| SCHEMBL1498618 | 0.82 | TDP1 (0.40) | KDM4EALDH1A1SMN1; SMN2GAAPOLB | |
| SCHEMBL1498500 | 0.81 | MEN1 (0.44) | KDM4EALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL1498502 | 0.81 | MEN1 (0.44) | KDM4EALDH1A1SMN1; SMN2GAAKMT2A | |
| SCHEMBL17161190 | 0.80 | MEN1 (0.39) | KDM4EALDH1A1SMN1; SMN2NPSR1GAA | |
| SCHEMBL20790978 | 0.79 | CYP1A2 (0.47) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL30525085 | 0.79 | CYP1A2 (0.47) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| EP-2477963-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Zalicus Pharmaceuticals Ltd. (CA) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011035159-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | KDM4E 3871/4885ALDH1A1 588/4885SMN1; SMN2 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.